Filter your results
- 3
- 1
- 4
- 4
- 1
- 2
- 1
- 4
- 4
- 4
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 3
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
4 Results
|
|
sorted by
|
|
Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trialHaematologica, 2015, 100 (6), pp.780 - 785. ⟨10.3324/haematol.2014.114884⟩
Journal articles
inserm-01820455v1
|
||
|
Unlike ASXL1 and ASXL2 mutations, ASXL3 mutations are rare events in acute myeloid leukemia with t(8;21)Leukemia & lymphoma, 2016, 57 (1), pp.199 - 200. ⟨10.3109/10428194.2015.1037754⟩
Journal articles
inserm-01820362v1
|
||
|
Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall StudyBlood, 2016, 128 (22), ⟨10.1182/blood.V128.22.2776.2776⟩
Journal articles
hal-03605054v1
|
||
|
Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroupScience Translational Medicine, 2021, 13 (595), pp.eabc4834. ⟨10.1126/scitranslmed.abc4834⟩
Journal articles
hal-03282998v1
|